News from the Cancer Centers: How DCIS Becomes Invasive Breast Cancer

Earlier this year, a study published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR), explored the question of how preinvasive breast tumors become invasive. The study’s lead author, Kornelia Polyak, MD, PhD, discussed the findings in an article published by Inside the Institute, a publication of Dana-Farber Cancer Institute.

Read More

Do Genomic Approaches to Selecting Cancer Treatment Yield Better Patient Outcomes Than Traditional Approaches?

A study published recently in the AACR’s journal Cancer Discovery addresses the burgeoning question of the utility of high-throughput genomic analysis in identifying targeted therapies and delivering better outcomes for cancer patients, and adds important evidence to argue in favor of such an approach. The jury, nevertheless, is still out.

Read More

Advances in Immunotherapy: Tackling CAR T-cell Therapy Resistance

In a study published in the AACR’s journal Cancer Discovery in December, a team of researchers from the Perelman School of Medicine and the Children’s Hospital of Philadelphia identified mechanisms by which some children’s B-cell leukemias develop resistance to CD19 CAR T-cell therapy, an investigational immunotherapy that yields long-lasting remissions in many patients with this disease.

Read More

Overcoming Drug Resistance: The EGFR Enigma

Currently, anti-EGFR therapies are approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, and colorectal cancer. Most patients receiving anti-EGFR therapies benefit from the treatment, but the challenge they face, as do patients receiving most other targeted therapies, is that their tumors ultimately develop drug resistance. So efforts are underway to develop newer anti-EGFR therapies that can circumvent resistance to existing EGFR inhibitors.

Read More

The Curious Case of the Exceptional Responder

The structure of a section of DNA

For decades, experimental cancer drugs that did not provide measurable benefit to a significant number of patients in a clinical trial were considered “failed,” and further efforts to develop the drug for that use were shelved. The few patients who responded to such drugs were thought to have experienced a “miracle.”

Read More